Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence

Annals of Oncology

Volumn 27, Issue 7, 2016, Pages 1241-1248

  Mittendorf, E A ^a   Ardavanis, A ^b   Symanowski, J ^c   Murray, J L ^a   Shumway, N M ^d,e   Litton, J K ^a   Hale, D F ^d   Perez, S A ^b   Anastasopoulou, E A ^b   Pistamaltzian, N F ^b   Ponniah, S ^e   Baxevanis, C N ^b   von Hofe, E ^f   Papamichail, M ^b   Peoples, G E ^e,g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c LEVINE CANCER INSTITUTE   (United States)

^d BROOKE ARMY MEDICAL CENTER   (United States)

^e Uniformed Services University of the Health Sciences   (United States)

^f Antigen Express   (United States)

^g Cancer Vaccine Development Program   (United States)

Author keywords

Breast cancer; HER2; Immunotherapy; Triple negative breast cancer; Vaccine

Indexed keywords

AE37 PEPTIDE; CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; UNCLASSIFIED DRUG; AE37 VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; PEPTIDE FRAGMENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; SINGLE BLIND PROCEDURE; TRIPLE NEGATIVE BREAST CANCER; UNSPECIFIED SIDE EFFECT; CLINICAL TRIAL; GENETICS; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; PREVENTION AND CONTROL; TUMOR RECURRENCE;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; CANCER VACCINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PEPTIDE FRAGMENTS; RECEPTOR, ERBB-2; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84977100884     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw150     Document Type: Article

References (20)

1. Mittendorf EA, Holmes JP, Ponniah S, Peoples GE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 2008; 57: 1511-1521.
2. Peoples GE, Holmes JP, Hueman MT et al. Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803.
3. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-728.
4. Knutson KL, Disis ML. Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 365-371.
5. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999; 5: 1289-1297.
6. Salazar LG, Fikes J, Southwood S et al. Immunization of cancer patients with HER- 2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003; 9: 5559-5565.
7. Sotiriadou R, Perez SA, Gritzapis AD et al. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. Br J Cancer 2001; 85: 1527-1534.
8. Tuttle TM, Anderson BW, Thompson WE et al. Proliferative and cytokine responses to class II HER-2/neu-associated peptides in breast cancer patients. Clin Cancer Res 1998; 4: 2015-2024.
9. Sears AK, Perez SA, Clifton GT et al. AE37: a novel T-cell-eliciting vaccine for breast cancer. Expert Opin Biol Ther 2011; 11: 1543-1550.
10. Adams S, Humphreys RE. Invariant chain peptides enhancing or inhibiting the presentation of antigenic peptides by major histocompatibility complex class II molecules. Eur J Immunol 1995; 25: 1693-1702.
11. Gillogly ME, Kallinteris NL, Xu M et al. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother 2004; 53: 490-496.
12. Humphreys RE, Adams S, Koldzic G et al. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 2000; 18: 2693-2697.
13. Sotiriadou NN, Kallinteris NL, Gritzapis AD et al. Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors. Cancer Immunol Immunother 2007; 56: 601-613.
14. Holmes JP, Benavides LC, Gates JD et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26: 3426-3433.
15. Sokal JE. Editorial: Measurement of delayed skin-test responses. N Engl J Med 1975; 293: 501-502.
16. Perez SA, Kallinteris NL, Bisias S et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010; 16: 3495-3506.
17. Mittendorf EA, Clifton GT, Holmes JP et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Ann Oncol 2014; 25: 1735-1742.
18. Clive KS, Tyler JA, Clifton GT et al. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines 2010; 9: 519-525.
19. Greene JM, Schneble EJ, Litton JK et al. Correlation of robust local reactions prompting GM-CSF dose reduction to clinical response in a phase II trial of the AE37+GM-CSF HER2 peptide vaccine. In Proceedings of the 106th Annual Meeting of the American Association for Cancer Research 2015 (Abstr #CT209), Philadelphia, PA.
20. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.